Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003 in EGFR-positive advanced non-small cell lung cancer
ChiCTR2000039157Phase 2Recruiting
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of becotatug vedotin in non-small cell lung cancer (NSCLC), sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective response rate. Started Dec 2020; status: recruiting.
02
Drugs
becotatug vedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000039157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039157.